Mallinckrodt Pharmaceuticals

Company snapshot

Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. From this union, we established two focused, standalone companies: – Keenova Therapeutics, a branded therapeutics business – Par Health, a generics and sterile injectables business To learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parh

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Mallinckrodt Pharmaceuticals. Not investment advice.

• What is Mallinckrodt Pharmaceuticals?

  Mallinckrodt Pharmaceuticals Ireland is a pharma organization headquartered in DUBLIN, IE. Primary therapeutic focus areas include Hyperbilirubinemia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinic

• Is Mallinckrodt Pharmaceuticals publicly traded?

  Mallinckrodt Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Mallinckrodt Pharmaceuticals develop or market?

  No drug profiles are currently linked to Mallinckrodt Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for Mallinckrodt Pharmaceuticals?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Mallinckrodt Pharmaceuticals focus on?

  Mallinckrodt Pharmaceuticals focuses on Hyperbilirubinemia based on our analysis of their pipeline programs and drug development activities.